Posts

Novartis and BMS pause autoimmune CAR-T trials after serious immune-related events

on

BMS Adds $173 Million to Radiopharmaceutical Manufacturing Expansion

on

Bristol Myers Ends Cellares Manufacturing Deal as Cell-Therapy Company Reorganizes

on

Cytokinetics Brings Patent Suit Against Bristol Myers, Escalating Rivalry

on

AbbVie, Novartis and Bristol Myers Squibb Sue Illinois Over 340B Contract Pharmacy Law

on

Bristol Myers Squibb Details New $2.3 Billion Manufacturing Campus in Houston

on

Merger talks between AstraZeneca and Bristol Myers Squibb are off, report says

on

Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?

on

Editors Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea summarized and explained

on

AstraZeneca and Bristol Myers Squibb in $400 Billion Merger Talks

on

BMS pushes key Cobenfy and milvexian readouts to 2027 amid strong quarter and raised guidance

on

BMS CEO Boerner Says No Compulsion to Chase Deals Despite Quiet M&A Year

on

BMS expands AI footprint with Nvidia, aiming for most powerful AI factory in life sciences

on

Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial

on

Bristol Myers details Krazati confirmatory study failure in colorectal cancer

on

Kardigan’s $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO

on

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Use AI and Real‑World Data to Improve Clinical Trial Success

on

Cytokinetics Succeeds Against Bristol Myers' Failure in HCM: FDA Approves Myqorzo as Camzyos Fails nHCM Trial

on

Bristol Myers Squibb's Pipeline Focus in Pivotal 2026

on

Bristol Myers Squibb and Bain Capital Launch New Autoimmune Disease Biotech Company

on